share_log

OncoSec Medical (NASDAQ:ONCS) Earns Sell Rating From Analysts at StockNews.com

kopsource ·  Dec 10, 2022 05:52

StockNews.com started coverage on shares of OncoSec Medical (NASDAQ:ONCS – Get Rating) in a research note released on Wednesday. The brokerage issued a sell rating on the biotechnology company's stock.

Separately, BTIG Research downgraded shares of OncoSec Medical from a buy rating to a neutral rating in a report on Monday, November 14th.

Get OncoSec Medical alerts:

OncoSec Medical Stock Performance

Shares of NASDAQ:ONCS opened at $1.84 on Wednesday. The company's 50-day moving average is $8.57 and its 200 day moving average is $13.45. The company has a market capitalization of $3.32 million, a P/E ratio of -0.09 and a beta of 1.48. OncoSec Medical has a fifty-two week low of $1.77 and a fifty-two week high of $33.88.

Institutional Investors Weigh In On OncoSec Medical

An institutional investor recently raised its position in OncoSec Medical stock. Bank of New York Mellon Corp raised its holdings in shares of OncoSec Medical Incorporated (NASDAQ:ONCS – Get Rating) by 653.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 386,074 shares of the biotechnology company's stock after purchasing an additional 334,849 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.98% of OncoSec Medical worth $444,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 13.22% of the company's stock.

OncoSec Medical Company Profile

(Get Rating)

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer.

Further Reading

  • Get a free copy of the StockNews.com research report on OncoSec Medical (ONCS)
  • MarketBeat: Week in Review 12/05 – 12/09
  • There Is Fundamental Value In Broadcom, And It Yields 3.35%
  • Costco vs Amazon: an end of the year showdown
  • Discount Retailers Could Make Good Bargain Stocks
  • Can Pfizer, Johnson & Johnson Continue Outperforming the Index?

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment